FDA will hear Sanofi's second plea for Lemtrada approval

There may be some light at the end of a long regulatory tunnel for Sanofi's ($SNY) Lemtrada. The company resubmitted its once-rejected multiple sclerosis treatment for FDA approval, hoping that a new analysis of old data will win over regulators. On Friday, the agency accepted Sanofi's supplemental application for consideration, and a 6-month review period follows. A final decision is expected in the fourth quarter of this year, the company said in a statement. Release (PDF) | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.